Government financing for health and specific national budget lines: The case of vaccines and immunization

Immunization Vaccines and Biologicals Department (IVB), Expanded Programme on Immunization (EPI), World Health Organization (WHO), Office: M235, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland.
Vaccine (Impact Factor: 3.62). 08/2008; 26(51):6727-34. DOI: 10.1016/j.vaccine.2008.06.090
Source: PubMed

ABSTRACT A long standing question related to immunization financing and sustainability has been whether the existence of a specific line item for vaccines purchasing within the national health budget can contribute significantly to increasing national government financing of vaccines and routine immunizations. Based on immunization financing indicators from 185 countries collected through the joint WHO and UNICEF monitoring system, this paper attempts to answer this policy question. The study will present findings related to the status of countries that have such specific budget lines for purchasing vaccines and the levels of national budgetary allocation to the financing of vaccines and immunizations, particularly in low-income countries. The analysis shows evidence that the existence ofa specific line in the national budget is associated with increased governmental budget allocations for vaccines and routine immunization financing.

23 Reads
  • Source
    • "The hepatitis B surface antigen is the basis of the vaccine against HBV that became available in the early 1980s, becoming the first vaccine for prevention of a human cancer (Blumberg, 2002). Although there have been issues related to coverage that have reduced the potential of the vaccine (Lydon et al, 2008), there is already evidence from a nationwide vaccination programme in Taiwan (Chang et al, 1997) that the HBV vaccine can reduce the incidence of liver cancer (Chang et al, 2009). As HBV vaccination is of newborns, we are just beginning to see the effect of a vaccine programme begun over 20 years ago. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Denis Parsons Burkitt was born in 1911, and in the late 1950s, described the disease that has come to be known as Burkitt lymphoma based on cases he observed in Uganda. Subsequently, Burkitt lymphoma was recognized as the first human tumour associated with an infectious agent when Epstein-Barr virus was isolated from samples supplied by Burkitt. It is now recognized that over one-quarter of cancers worldwide are tied to infections. Notably, liver cancer is linked to hepatitis B virus and hepatitis C virus infections, and cervical cancer to infections involving the human papilloma viruses. In addition, immunocompromise arising from infection with the human immunodeficiency virus allows tumours (e.g., Kaposi sarcoma) caused by other viruses to arise. More than 50 years after the seminal paper by Burkitt based on his work in Africa, it is appreciated that the contribution of viral infections to cancers remains considerably higher in sub-Saharan Africa than in the rest of the world.
    British Journal of Haematology 03/2012; 156(6):709-18. DOI:10.1111/j.1365-2141.2011.09017.x · 4.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vaccination is among the most cost-effective health interventions and has attracted ever greater levels of funding from public and private donors. However, some countries, mainly populous lower-middle income countries, are lagging behind on vaccination financing and performance. In this paper, we discuss the rationale for investing in vaccination and construct a metric to measure government commitment to vaccination that could promote accountability and better tracking of performance. While noting the limitations of available data, we find that populous middle-income countries, which stand to gain tremendously from increased vaccination uptake, perform poorly in terms of their vaccination outcomes.
    Vaccine 04/2013; 31:B32–B42. DOI:10.1016/j.vaccine.2012.12.036 · 3.62 Impact Factor
Show more


23 Reads
Available from